ArticleInternational urology and nephrology2026
Bladder-sparing therapy for high-tumor-burden non-muscle invasive bladder cancer: outcomes from high-tumor-burden NMIBC program.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeThe management of high-tumor-burden non-muscle invasive bladder cancer remains challenging due to risks of incomplete resection, perioperative complications, and eventual cystectomy. This study aims to evaluate the feasibility and outcomes associated with the implementation of the High-Tumor-Burden NMIBC Program.
methodsThis multicenter retrospective study analyzed patients from five tertiary care centers who enrolled in the High-Tumor-Burden NMIBC Program between January 2019 and January 2024. Key interventions comprised: (1) endoscopic bladder tumor burden assessment, (2) staged resection for massive lesions, (3) superficial resection for flat-like tumors, (4) targeted detrusor muscle sampling, (5) extraction of tumor with the siphon effect, and (6) intravesical BCG instillations. Survival curves were generated using the Kaplan-Meier method, with differences assessed by the log-rank test.
resultsWith a median follow-up time of 2.5 years, complete macroscopic resection was achieved in all patients, with 36 patients (18.2%) receiving a second and 4 patients (2.0%) receiving a third session. During the entire follow-up period, 186 patients (93.9%) preserved their bladders. High-grade recurrence-free survival rates at 1 and 3 years were 92.7% and 86.9%, and progression-free survival rates were 100.0% and 91.1%. Cystectomy-free survival rates at 1 and 3 years were 100% and 95.7%, and overall survival rates were 99.0% and 94.7%.
conclusionThis study suggests the feasibility of implementing the High-Tumor-Burden NMIBC Program, achieving high rates of complete resection and bladder preservation with acceptable oncologic outcomes during intermediate follow-up.
Indexed as
Identifiers
41152653What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.